abstract |
The present invention relates to stable, high-concentration, low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations, and methods of treatment using the formulations and kits for inhibiting adverse effects of MASP-2-dependent complement activation . |